(Q40861609)

24 September 2017

1 reference

title

Cefepime clinical pharmacokinetics (English)

1 reference

24 September 2017

1 reference

M P Okamoto

1

1 reference

24 September 2017

R K Nakahiro

series ordinal

2

1 reference

24 September 2017

A Chin

series ordinal

3

1 reference

24 September 2017

A Bedikian

series ordinal

4

1 reference

24 September 2017

1 August 1993

1 reference

Clinical Pharmacokinetics

24 September 2017

1 reference

24 September 2017

25

1 reference

24 September 2017

88-102

1 reference

24 September 2017

2

1 reference

https://scigraph.springernature.com/pub.10.2165/00003088-199325020-00002

24 September 2017

0 references

cites work

Effects of age and gender on pharmacokinetics of cefepime

1 reference

12 December 2020

Efficacy of BMY-28142 in experimental bacteremia and meningitis caused by Escherichia coli and group B streptococci

1 reference

12 December 2020

Cephalosporin penetration into soft tissue of paralyzed limbs

1 reference

12 December 2020

In vitro evaluation of HR810, a new wide-spectrum aminothiazolyl alpha-methoxyimino cephalosporin

1 reference

12 December 2020

In vitro studies of BMY-28142, a new broad-spectrum cephalosporin

1 reference

12 December 2020

Clindamycin treatment of experimental chronic osteomyelitis due to Staphylococcus aureus

1 reference

12 December 2020

Affinity of cephalosporins for beta-lactamases as a factor in antibacterial efficacy

1 reference

12 December 2020

In vitro activity of fleroxacin and 6 other antimicrobials against Acinetobacter anitratus

1 reference

12 December 2020

Comparative Multiple-Dose Pharmacokinetics of Cefotaxime, Moxalactam, and Ceftazidime

1 reference

12 December 2020

Experimental Osteomyelitis. IV. Therapeutic Trials with Rifampin Alone and in Combination with Gentamicin, Sisomicin, and Cephalothin

1 reference

12 December 2020

In vitro antibacterial activity of BMY-28142, a new extended-spectrum cephalosporin

1 reference

12 December 2020

Antibacterial activity of BMY-28142, a novel broad-spectrum cephalosporin.

1 reference

12 December 2020

Third generation cephalosporins: safety profiles after 10 years of clinical use.

1 reference

12 December 2020

Activity of cefepime against ceftazidime- and cefotaxime-resistant gram-negative bacteria and its relationship to beta-lactamase levels

1 reference

12 December 2020

An evaluation of the penetration of cefepime into prostate tissue in patients undergoing elective prostatectomy

1 reference

12 December 2020

Pharmacokinetics and pharmacodynamics of cefoperazone-sulbactam in patients on continuous ambulatory peritoneal dialysis

1 reference

12 December 2020

Combination effect of SCE-2787 and cefepime with aminoglycosides on nosocomial gram-negative bacteria

1 reference

12 December 2020

Pharmacokinetics of cefepime in subjects with renal insufficiency

1 reference

12 December 2020

Comparison of a new cephalosporin, BMY 28142, with other broad-spectrum beta-lactam antibiotics

1 reference

12 December 2020

Pharmacokinetics of cefepime in patients undergoing continuous ambulatory peritoneal dialysis

1 reference

12 December 2020

Disposition of the cephalosporin cefepime in normal and renally impaired subjects

1 reference

12 December 2020

Pharmacokinetics and tissue penetration of cefepime

1 reference

12 December 2020

Comparative in vitro evaluation of BMY-28142, a new broad-spectrum cephalosporin, versus other beta-lactams against multiresistant gram-negative isolates.

1 reference

12 December 2020

Cefepime concentrations in bronchial mucosa and serum following a single 2 gram intravenous dose.

1 reference

12 December 2020

Evaluation of the in vitro activity of BMY-28142, a new broad-spectrum cephalosporin

1 reference

12 December 2020

In vitro susceptibility of methicillin-resistant Staphylococcus aureus to imipenem and other antimicrobial agents.

1 reference

12 December 2020

Simplified, accurate method for antibiotic assay of clinical specimens

1 reference

12 December 2020

Safety, tolerance, and pharmacokinetic evaluation of cefepime after administration of single intravenous doses

1 reference

12 December 2020

Ceftriaxone pharmacokinetics during peritoneal dialysis

1 reference

12 December 2020

Cefepime pharmacokinetics in patients with acute cholecystitis undergoing cholecystectomy.

1 reference

12 December 2020

Clinical and laboratory evidence for inactivation of gentamicin by carbenicillin.

1 reference

12 December 2020

Safety, tolerance, and pharmacokinetics of cefepime administered intramuscularly to healthy subjects

1 reference

12 December 2020

Development of beta-lactam-resistant Enterobacter cloacae in mice.

1 reference

12 December 2020

In-vitro activity of BMY 28142, a new aminothiazolyl cephalosporin.

1 reference

12 December 2020

Cefepime for treatment of experimental chronic osteomyelitis due to Staphylococcus aureus

1 reference

12 December 2020

Comparison of the in vitro and in vivo antibacterial activities of cefepime (BMY-28142) with ceftazidime, cefuzonam, cefotaxime and cefmenoxime

1 reference

12 December 2020

The influence of cefepime on opsonophagocytosis of bacteria.

1 reference

12 December 2020

Novel method for measurement of outer membrane permeability to new beta-lactams in intact Enterobacter cloacae cells

1 reference

12 December 2020

The importance of pharmacodynamics in determining the dosing interval in therapy for experimental pseudomonas endocarditis in the rat

1 reference

12 December 2020

Comparative in vitro activity of cefepime (BMY 28142) against multiresistant nosocomial isolates of Pseudomonas aeruginosa.

1 reference

12 December 2020

Experimental Osteomyelitis. V. Therapeutic Trials with Oxacillin and Sisomicin Alone and in Combination

1 reference

12 December 2020

Comparative study of the effects of four cephalosporins against Escherichia coli in vitro and in vivo

1 reference

12 December 2020

BMY28142, cefbuperazone (T-1982), and Sch 34343. Antimicrobial activity against 94 anaerobes compared to seven other antimicrobial agents

1 reference

12 December 2020

Activity of cefepime (BMY-28142) and cefpirome (HR 810) against gram-negative bacilli resistant to cefotaxime or ceftazidime

1 reference

12 December 2020

In vitro activity of BRL 36650, a new penicillin

1 reference

12 December 2020

Tissue concentrations of cefepime in acute cholecystitis patients

1 reference

12 December 2020

The antibiotic sensitivity of bacteria isolated from the blood of patients in St Thomas' Hospital, 1969-1988.

1 reference

12 December 2020

The activity of BMY 28142 a new broad spectrum beta-lactamase stable cephalosporin

1 reference

12 December 2020

Pharmacokinetics of ceftazidime in patients undergoing peritoneal dialysis

1 reference

12 December 2020

High-pressure liquid chromatographic analysis of BMY-28142 in plasma and urine

1 reference

12 December 2020

Comparative in vitro activity of cefpirome and cefepime, two new cephalosporins

1 reference

12 December 2020

In vitro activity of BMY-28142 against pediatric pathogens, including isolates from cystic fibrosis sputum

1 reference

12 December 2020

Pharmacokinetics of cefpirome (HR 810), a new cephalosporin derivative administered intramuscularly and intravenously to healthy volunteers

1 reference

12 December 2020

Frequency of in vitro resistance of Pseudomonas aeruginosa to cefepime, ceftazidime, and cefotaxime

1 reference

12 December 2020

New cephalosporins cefotaxime, cefpimizole, BMY 28142, and HR 810 in experimental pneumococcal meningitis in rabbits

1 reference

12 December 2020

In vitro activity of BMY-28142 in comparison with those of other beta-lactam antimicrobial agents

1 reference

12 December 2020

Activities of beta-lactam antibiotics against Escherichia coli strains producing extended-spectrum beta-lactamases

1 reference

12 December 2020

Safety, tolerance and pharmacokinetics of 2.0 g cefpirome (HR 810) after single and multiple dosing

1 reference

12 December 2020

Factors involved in the enhanced efficacy against gram-negative bacteria of fourth generation cephalosporins

1 reference

12 December 2020

Open trial of cefepime (BMY 28142) for infections in hospitalized patients

1 reference

12 December 2020

Experimental Osteomyelitis. II. Therapeutic Trials and Measurement of Antibiotic Levels in Bone

1 reference

12 December 2020

Pharmacokinetics of cefepime dihydrochloride arginine in subjects with renal impairment

1 reference

12 December 2020

Type I beta-lactamases of gram-negative bacteria: interactions with beta-lactam antibiotics

1 reference

12 December 2020

In vitro activity of E-1040, a novel cephalosporin with potent activity against Pseudomonas aeruginosa

1 reference

12 December 2020

In vitro activity of carumonam (RO 17-2301), BMY-28142, aztreonam, and ceftazidime against 7,620 consecutive clinical bacterial isolates

1 reference

12 December 2020

Multiple-dose pharmacokinetics of ceftazidime and its influence on fecal flora

1 reference

12 December 2020

Pharmacokinetics of cefepime in patients with respiratory tract infections

1 reference

12 December 2020

In-vitro activity of cefpirome (HR-810), WIN-49375, BMY-28142 and other antibiotics against nosocomially important isolates from cancer patients

1 reference

12 December 2020

Ceftizoxime elimination kinetics in continuous ambulatory peritoneal dialysis

1 reference

12 December 2020

Comparative in vitro antibacterial activity of the new carbapenem meropenem (SM-7338).

1 reference

12 December 2020

Therapeutic studies of cefepime (BMY 28142) in murine meningitis and pharmacokinetics in neonatal rats

1 reference

12 December 2020

Ceftazidime. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

1 reference

12 December 2020

In vitro inactivation of aminoglycosides by cephalosporin antibiotics

1 reference

12 December 2020

In vitro activity and beta-lactamase stability of GR69153, a new long-acting cephalosporin

1 reference

12 December 2020

Outer membrane permeability and beta-lactamase stability of dipolar ionic cephalosporins containing methoxyimino substituents

1 reference

12 December 2020

In vitro activity of BMY-28142, a new cephalosporin

1 reference

12 December 2020

Cephalosporinase interactions and antimicrobial activity of BMY-28142, ceftazidime and cefotaxime.

1 reference

12 December 2020

HR 810 and BMY-28142, two new cephalosporins with broad-spectrum activity: an in-vitro comparison with other beta-lactam antibiotics

1 reference

12 December 2020

The use of cefepime (BMY 28142) to treat respiratory infections

1 reference

12 December 2020

Pharmacokinetic disposition and bactericidal activities of cefepime, ceftazidime, and cefoperazone in serum and blister fluid

1 reference

12 December 2020

Pharmacokinetics of the novel cephalosporin cefepime (BMY-28142) in rats and monkeys

1 reference

12 December 2020

Synthesis and structure-activity relationships of a new series of cephalosporins, BMY-28142 and related compounds

1 reference

12 December 2020

In vitro activity of cefepime, a new parenteral cephalosporin, against recent European blood isolates and in comparison with piperacillin/tazobactam

1 reference

12 December 2020

Cefepime. Pharmacokinetics and clinical response in patients with cystic fibrosis

1 reference

12 December 2020

Role of beta-lactam hydrolysis in the mechanism of resistance of a beta-lactamase-constitutive Enterobacter cloacae strain to expanded-spectrum beta-lactams

1 reference

12 December 2020

Tentative disk diffusion susceptibility interpretive criteria for BMY-28142, a new cephalosporin.

1 reference

12 December 2020

Trapping of nonhydrolyzable cephalosporins by cephalosporinases in Enterobacter cloacae and Pseudomonas aeruginosa as a possible resistance mechanism

1 reference

12 December 2020

beta-Lactamases and beta-lactam resistance in Escherichia coli

1 reference

12 December 2020

Analysis of cefepime tissue penetration into human appendix

1 reference

12 December 2020

Pharmacokinetics of cefepime after single and multiple intravenous administrations in healthy subjects

1 reference

12 December 2020

Activity of cefepime, ceftazidime, and ceftizoxime against mutants of Enterobacteriaceae and Pseudomonas aeruginosa derepressed for class I beta-lactamase

1 reference

12 December 2020

Lack of pharmacokinetic interaction between cefepime and amikacin in humans

1 reference

12 December 2020

Pharmacokinetics of beta-lactam antibiotics

1 reference

12 December 2020

Antimicrobial activities of BMY-28142, cefbuperazone, and cefpiramide compared with those of other cephalosporins

1 reference

12 December 2020

Treatment of experimental chronic osteomyelitis due to staphylococcus aureus with vancomycin and rifampin

1 reference

12 December 2020

10.2165/00003088-199325020-00002

Identifiers

DOI

1 reference

Dimensions Publication ID

24 September 2017

0 references

1 reference